Covalon Technologies (CVE:COV) Hits New 12-Month High at $3.31

Covalon Technologies Ltd. (CVE:COV) reached a new 52-week high during trading on Tuesday . The company traded as high as C$3.31 and last traded at C$3.20, with a volume of 47076 shares trading hands. The stock had previously closed at C$3.17.

Covalon Technologies Trading Up 2.5 %

The company has a debt-to-equity ratio of 4.98, a quick ratio of 6.45 and a current ratio of 5.24. The firm has a market capitalization of C$80.18 million, a P/E ratio of -81.25 and a beta of 0.64. The firm has a 50 day simple moving average of C$2.57 and a two-hundred day simple moving average of C$1.85.

Covalon Technologies (CVE:COV) last released its quarterly earnings results on Wednesday, August 21st. The company reported C$0.06 earnings per share for the quarter. Covalon Technologies had a negative net margin of 2.82% and a negative return on equity of 3.85%. The company had revenue of C$9.22 million for the quarter. Equities research analysts forecast that Covalon Technologies Ltd. will post 0.3 earnings per share for the current year.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.